Sivik Global Healthcare LLC Has $5.07 Million Stock Position in Humana Inc. (NYSE:HUM)

Sivik Global Healthcare LLC increased its stake in Humana Inc. (NYSE:HUM) by 100.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 20,000 shares of the insurance provider’s stock after acquiring an additional 10,000 shares during the quarter. Humana comprises 2.7% of Sivik Global Healthcare LLC’s holdings, making the stock its 17th largest holding. Sivik Global Healthcare LLC’s holdings in Humana were worth $5,074,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Atlas Brown Inc. grew its holdings in Humana by 0.6% during the fourth quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock valued at $1,611,000 after purchasing an additional 38 shares during the period. Moors & Cabot Inc. boosted its stake in shares of Humana by 2.5% in the third quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock worth $519,000 after acquiring an additional 40 shares during the period. OLD National Bancorp IN boosted its stake in shares of Humana by 1.8% in the third quarter. OLD National Bancorp IN now owns 2,613 shares of the insurance provider’s stock worth $828,000 after acquiring an additional 45 shares during the period. Your Advocates Ltd. LLP boosted its stake in Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after buying an additional 45 shares during the last quarter. Finally, Brooklyn Investment Group boosted its stake in Humana by 6.7% during the third quarter. Brooklyn Investment Group now owns 736 shares of the insurance provider’s stock valued at $233,000 after buying an additional 46 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Stock Down 0.5 %

Shares of NYSE HUM opened at $292.81 on Thursday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $35.26 billion, a PE ratio of 26.02, a price-to-earnings-growth ratio of 2.15 and a beta of 0.55. The stock’s fifty day simple moving average is $275.44 and its two-hundred day simple moving average is $303.14. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.68. The business had revenue of $29.30 billion for the quarter, compared to analysts’ expectations of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. As a group, analysts expect that Humana Inc. will post 16.11 EPS for the current fiscal year.

Insider Transactions at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.32% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on HUM shares. Morgan Stanley raised their price objective on Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 17th. Sanford C. Bernstein raised Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price objective for the company in a research note on Tuesday, October 8th. Piper Sandler raised their price objective on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft reduced their price target on Humana from $349.00 to $250.00 and set a “hold” rating on the stock in a report on Thursday, October 3rd. Finally, TD Cowen increased their price target on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Nineteen equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $297.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.